889 related articles for article (PubMed ID: 38473776)
21. The Role of Microglia in Glioblastoma.
Geribaldi-Doldán N; Fernández-Ponce C; Quiroz RN; Sánchez-Gomar I; Escorcia LG; Velásquez EP; Quiroz EN
Front Oncol; 2020; 10():603495. PubMed ID: 33585220
[TBL] [Abstract][Full Text] [Related]
22. The role of E3 ubiquitin ligases in the development and progression of glioblastoma.
Humphreys LM; Smith P; Chen Z; Fouad S; D'Angiolella V
Cell Death Differ; 2021 Feb; 28(2):522-537. PubMed ID: 33432111
[TBL] [Abstract][Full Text] [Related]
23. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B
Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530
[TBL] [Abstract][Full Text] [Related]
24. Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation.
Peterziel H; Müller J; Danner A; Barbus S; Liu HK; Radlwimmer B; Pietsch T; Lichter P; Schütz G; Hess J; Angel P
Neuro Oncol; 2012 Apr; 14(4):426-39. PubMed ID: 22394497
[TBL] [Abstract][Full Text] [Related]
25. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option.
Asija S; Chatterjee A; Goda JS; Yadav S; Chekuri G; Purwar R
Front Immunol; 2023; 14():1118246. PubMed ID: 37006286
[TBL] [Abstract][Full Text] [Related]
27. Cancer Metabolism: The Role of Immune Cells Epigenetic Alteration in Tumorigenesis, Progression, and Metastasis of Glioma.
Kanwore K; Kanwore K; Adzika GK; Abiola AA; Guo X; Kambey PA; Xia Y; Gao D
Front Immunol; 2022; 13():831636. PubMed ID: 35392088
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab for the treatment of glioblastoma.
Chowdhary S; Chamberlain M
Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy: a promising approach for glioma treatment.
Yasinjan F; Xing Y; Geng H; Guo R; Yang L; Liu Z; Wang H
Front Immunol; 2023; 14():1255611. PubMed ID: 37744349
[TBL] [Abstract][Full Text] [Related]
30. Current Advances in Immunotherapy for Glioblastoma.
Mende AL; Schulte JD; Okada H; Clarke JL
Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
[TBL] [Abstract][Full Text] [Related]
31. Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives.
Duerinck J; Tuyaerts S; Movahedi K; Neyns B
Front Immunol; 2023; 14():1183641. PubMed ID: 37275902
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.
Shoaf ML; Desjardins A
Neurotherapeutics; 2022 Oct; 19(6):1818-1831. PubMed ID: 35674873
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications.
Das S; Dash BS; Premji TP; Chen JP
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445721
[TBL] [Abstract][Full Text] [Related]
34. Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities.
Linares CA; Varghese A; Ghose A; Shinde SD; Adeleke S; Sanchez E; Sheriff M; Chargari C; Rassy E; Boussios S
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686020
[TBL] [Abstract][Full Text] [Related]
35. MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy.
Miles X; Vandevoorde C; Hunter A; Bolcaen J
Front Oncol; 2021; 11():703442. PubMed ID: 34307171
[TBL] [Abstract][Full Text] [Related]
36. Human Glioblastoma-Derived Mesenchymal Stem Cell to Pericytes Transition and Angiogenic Capacity in Glioblastoma Microenvironment.
Yi D; Xiang W; Zhang Q; Cen Y; Su Q; Zhang F; Lu Y; Zhao H; Fu P
Cell Physiol Biochem; 2018; 46(1):279-290. PubMed ID: 29590646
[TBL] [Abstract][Full Text] [Related]
37. Targeting role of glioma stem cells for glioblastoma multiforme.
Zhang X; Zhang W; Mao XG; Zhen HN; Cao WD; Hu SJ
Curr Med Chem; 2013; 20(15):1974-84. PubMed ID: 23317162
[TBL] [Abstract][Full Text] [Related]
38. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
39. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
40. Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies.
Attia N; Mashal M; Pemminati S; Omole A; Edmondson C; Jones W; Priyadarshini P; Mughal T; Aziz P; Zenick B; Perez A; Lacken M
Cells; 2021 Dec; 11(1):. PubMed ID: 35011678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
